Cargando…
Astragaloside IV Ameliorates Airway Inflammation in an Established Murine Model of Asthma by Inhibiting the mTORC1 Signaling Pathway
Astragaloside IV (AS-IV), a main active constituent of Astragalus membranaceus, has been confirmed to have antiasthmatic effects. However, it remained unclear whether the beneficial effects of AS-IV on asthma were attributed to the mTOR inhibition; this issue was the focus of the present work. BALB/...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5676443/ https://www.ncbi.nlm.nih.gov/pubmed/29234390 http://dx.doi.org/10.1155/2017/4037086 |
_version_ | 1783277069364363264 |
---|---|
author | Jin, Hualiang Wang, Limin Li, Bei Cai, Cui Ye, Jian Xia, Junbo Ma, Shenglin |
author_facet | Jin, Hualiang Wang, Limin Li, Bei Cai, Cui Ye, Jian Xia, Junbo Ma, Shenglin |
author_sort | Jin, Hualiang |
collection | PubMed |
description | Astragaloside IV (AS-IV), a main active constituent of Astragalus membranaceus, has been confirmed to have antiasthmatic effects. However, it remained unclear whether the beneficial effects of AS-IV on asthma were attributed to the mTOR inhibition; this issue was the focus of the present work. BALB/c mice were sensitized and challenged with ovalbumin followed with 3 weeks of rest/recovery and then reexposure to ovalbumin. AS-IV was administrated during the time of rest and reexposure. The characteristic features of allergic asthma, including airway hyperreactivity, histopathology, cytokines (IL-4, IL-5, IL-13, IL-17, and INF-γ), and CD4(+)CD25(+)Foxp3(+)Treg cells in bronchoalveolar lavage fluid (BALF), and downstream proteins of mTORC1/2 signaling were examined. AS-IV markedly suppressed airway hyperresponsiveness and reduced IL-4, IL-5, and IL-17 levels and increased INF-γ levels in the BALF. Histological studies showed that AS-IV markedly decreased inflammatory infiltration in the lung tissues. Notably, AS-IV inhibited mTORC1 activity, whereas it had limited effects on mTORC2, as assessed by phosphorylation of mTORC1 and mTORC2 substrates S6 ribosomal protein, p70 S6 Kinase, and Akt, respectively. CD4(+)CD25(+)Foxp3(+)Treg cells in BALF were not significantly changed by AS-IV. Together, these results suggest that the antiasthmatic effects of AS-IV were at least partially from inhibiting the mTORC1 signaling pathway. |
format | Online Article Text |
id | pubmed-5676443 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-56764432017-12-11 Astragaloside IV Ameliorates Airway Inflammation in an Established Murine Model of Asthma by Inhibiting the mTORC1 Signaling Pathway Jin, Hualiang Wang, Limin Li, Bei Cai, Cui Ye, Jian Xia, Junbo Ma, Shenglin Evid Based Complement Alternat Med Research Article Astragaloside IV (AS-IV), a main active constituent of Astragalus membranaceus, has been confirmed to have antiasthmatic effects. However, it remained unclear whether the beneficial effects of AS-IV on asthma were attributed to the mTOR inhibition; this issue was the focus of the present work. BALB/c mice were sensitized and challenged with ovalbumin followed with 3 weeks of rest/recovery and then reexposure to ovalbumin. AS-IV was administrated during the time of rest and reexposure. The characteristic features of allergic asthma, including airway hyperreactivity, histopathology, cytokines (IL-4, IL-5, IL-13, IL-17, and INF-γ), and CD4(+)CD25(+)Foxp3(+)Treg cells in bronchoalveolar lavage fluid (BALF), and downstream proteins of mTORC1/2 signaling were examined. AS-IV markedly suppressed airway hyperresponsiveness and reduced IL-4, IL-5, and IL-17 levels and increased INF-γ levels in the BALF. Histological studies showed that AS-IV markedly decreased inflammatory infiltration in the lung tissues. Notably, AS-IV inhibited mTORC1 activity, whereas it had limited effects on mTORC2, as assessed by phosphorylation of mTORC1 and mTORC2 substrates S6 ribosomal protein, p70 S6 Kinase, and Akt, respectively. CD4(+)CD25(+)Foxp3(+)Treg cells in BALF were not significantly changed by AS-IV. Together, these results suggest that the antiasthmatic effects of AS-IV were at least partially from inhibiting the mTORC1 signaling pathway. Hindawi 2017 2017-10-25 /pmc/articles/PMC5676443/ /pubmed/29234390 http://dx.doi.org/10.1155/2017/4037086 Text en Copyright © 2017 Hualiang Jin et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Jin, Hualiang Wang, Limin Li, Bei Cai, Cui Ye, Jian Xia, Junbo Ma, Shenglin Astragaloside IV Ameliorates Airway Inflammation in an Established Murine Model of Asthma by Inhibiting the mTORC1 Signaling Pathway |
title | Astragaloside IV Ameliorates Airway Inflammation in an Established Murine Model of Asthma by Inhibiting the mTORC1 Signaling Pathway |
title_full | Astragaloside IV Ameliorates Airway Inflammation in an Established Murine Model of Asthma by Inhibiting the mTORC1 Signaling Pathway |
title_fullStr | Astragaloside IV Ameliorates Airway Inflammation in an Established Murine Model of Asthma by Inhibiting the mTORC1 Signaling Pathway |
title_full_unstemmed | Astragaloside IV Ameliorates Airway Inflammation in an Established Murine Model of Asthma by Inhibiting the mTORC1 Signaling Pathway |
title_short | Astragaloside IV Ameliorates Airway Inflammation in an Established Murine Model of Asthma by Inhibiting the mTORC1 Signaling Pathway |
title_sort | astragaloside iv ameliorates airway inflammation in an established murine model of asthma by inhibiting the mtorc1 signaling pathway |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5676443/ https://www.ncbi.nlm.nih.gov/pubmed/29234390 http://dx.doi.org/10.1155/2017/4037086 |
work_keys_str_mv | AT jinhualiang astragalosideivamelioratesairwayinflammationinanestablishedmurinemodelofasthmabyinhibitingthemtorc1signalingpathway AT wanglimin astragalosideivamelioratesairwayinflammationinanestablishedmurinemodelofasthmabyinhibitingthemtorc1signalingpathway AT libei astragalosideivamelioratesairwayinflammationinanestablishedmurinemodelofasthmabyinhibitingthemtorc1signalingpathway AT caicui astragalosideivamelioratesairwayinflammationinanestablishedmurinemodelofasthmabyinhibitingthemtorc1signalingpathway AT yejian astragalosideivamelioratesairwayinflammationinanestablishedmurinemodelofasthmabyinhibitingthemtorc1signalingpathway AT xiajunbo astragalosideivamelioratesairwayinflammationinanestablishedmurinemodelofasthmabyinhibitingthemtorc1signalingpathway AT mashenglin astragalosideivamelioratesairwayinflammationinanestablishedmurinemodelofasthmabyinhibitingthemtorc1signalingpathway |